The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models

被引:5
|
作者
Kelly, Rachel [1 ]
Cairns, Andrew G. [2 ]
Aden, Jorgen [2 ]
Almqvist, Fredrik [2 ]
Bemelmans, Alexis-Pierre [3 ]
Brouillet, Emmanuel [3 ]
Patton, Tommy [1 ]
McKernan, Declan P. [1 ]
Dowd, Eilis [1 ]
机构
[1] Natl Univ Ireland Galway, Pharmacol & Therapeut & Galway Neurosci Ctr, Galway H91 W5P7, Ireland
[2] Umea Univ, Dept Chem, S-90187 Umea, Sweden
[3] Univ Paris Saclay, CNRS, CEA, Lab Malad Neurodegenerat,MIRCen, F-92265 Fontenay Aux Roses, France
基金
爱尔兰科学基金会; 瑞典研究理事会;
关键词
Parkinson's; alpha-synuclein; adeno-associated virus; AAV; phospho-alpha-synuclein; DOPAMINERGIC NEURON LOSS; PARKINSONS-DISEASE; NIGROSTRIATAL NEURODEGENERATION; MEDIATED OVEREXPRESSION; MESSENGER-RNA; CORRIDOR TASK; PHOSPHORYLATION; PESTICIDE; GENE;
D O I
10.3390/biom11111685
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Animal models of Parkinson's disease, in which the human alpha-synuclein transgene is overexpressed in the nigrostriatal pathway using viral vectors, are widely considered to be the most relevant models of the human condition. However, although highly valid, these models have major limitations related to reliability and variability, with many animals exhibiting pronounced alpha-synuclein expression failing to demonstrate nigrostriatal neurodegeneration or motor dysfunction. Therefore, the aim of this study was to determine if sequential intra-nigral administration of AAV-alpha-synuclein followed by the small alpha-synuclein aggregating molecule, FN075, would enhance or precipitate the associated alpha-synucleinopathy, nigrostriatal pathology and motor dysfunction in subclinical models. Rats were given unilateral intra-nigral injections of AAV-alpha-synuclein (either wild-type or A53T mutant) followed four weeks later by a unilateral intra-nigral injection of FN075, after which they underwent behavioral testing for lateralized motor functionality until they were sacrificed for immunohistological assessment at 20 weeks after AAV administration. In line with expectations, both of the AAV vectors induced widespread overexpression of human alpha-synuclein in the substantia nigra and striatum. Sequential administration of FN075 significantly enhanced the alpha-synuclein pathology with increased density and accumulation of the pathological form of the protein phosphorylated at serine 129 (pS129-alpha-synuclein). However, despite this enhanced alpha-synuclein pathology, FN075 did not precipitate nigrostriatal degeneration or motor dysfunction in these subclinical AAV models. In conclusion, FN075 holds significant promise as an approach to enhancing the alpha-synuclein pathology in viral overexpression models, but further studies are required to determine if alternative administration regimes for this molecule could improve the reliability and variability in these models.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain
    Delenclos, Marion
    Faroqi, Ayman H.
    Yue, Mei
    Kurti, Aishe
    Castanedes-Casey, Monica
    Rousseau, Linda
    Phillips, Virginia
    Dickson, Dennis W.
    Fryer, John D.
    McLean, Pamela J.
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2017, 5 : 51
  • [22] Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain
    Marion Delenclos
    Ayman H. Faroqi
    Mei Yue
    Aishe Kurti
    Monica Castanedes-Casey
    Linda Rousseau
    Virginia Phillips
    Dennis W. Dickson
    John D. Fryer
    Pamela J. McLean
    Acta Neuropathologica Communications, 5
  • [23] Correction to: Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models
    Panagiota Mavroeidi
    Fedra Arvanitaki
    Anastasia-Kiriaki Karakitsou
    Maria Vetsi
    Ismini Kloukina
    Markus Zweckstetter
    Karin Giller
    Stefan Becker
    Zachary A. Sorrentino
    Benoit I. Giasson
    Poul Henning Jensen
    Leonidas Stefanis
    Maria Xilouri
    Acta Neuropathologica, 2019, 138 : 675 - 675
  • [24] Alpha-synuclein in cutaneous small nerve fibers
    Siepmann, Timo
    Illigens, Ben Min-Woo
    Barlinn, Kristian
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 2731 - 2735
  • [25] Cellular models of alpha-synuclein toxicity and aggregation
    Delenclos, Marion
    Burgess, Jeremy D.
    Lamprokostopoulou, Agaristi
    Outeiro, Tiago F.
    Vekrellis, Kostas
    McLean, Pamela J.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 (05) : 566 - 576
  • [26] In vivo models of alpha-synuclein transmission and propagation
    Ariadna Recasens
    Ayse Ulusoy
    Philipp J. Kahle
    Donato A. Di Monte
    Benjamin Dehay
    Cell and Tissue Research, 2018, 373 : 183 - 193
  • [27] Distribution of alpha-synuclein in rat salivary glands
    Nishitani, Tomiko
    Mitoh, Yoshihiro
    Yajima, Takehiro
    Tachiya, Daisuke
    Hoshika, Tomohiro
    Fukunaga, Tomohiro
    Nishitani, Yoshihiro
    Yoshida, Ryusuke
    Mizoguchi, Itaru
    Ichikawa, Hiroyuki
    Sato, Tadasu
    ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY, 2024, 307 (08): : 2933 - 2946
  • [28] Addressing pathological alpha-synuclein aggregation using a small molecule strategy
    Tsika, E.
    Ait-Bouziad, N.
    Dreyfus, N.
    Vallet, C.
    Maliqi, L.
    Aeschbach, L.
    Pautet, S.
    Menant, S.
    Borovko, I.
    Rey-Bellet, L.
    Ouared, A.
    Migliorini, R.
    Piorkowska, K.
    Darmency, V.
    Kroth, H.
    Poli, S.
    Pfeifer, A.
    Kosco-Vilbois, M.
    MOVEMENT DISORDERS, 2022, 37 : S474 - S475
  • [29] In vivo models of alpha-synuclein transmission and propagation
    Recasens, Ariadna
    Ulusoy, Ayse
    Kahle, Philipp J.
    Di Monte, Donato A.
    Dehay, Benjamin
    CELL AND TISSUE RESEARCH, 2018, 373 (01) : 183 - 193
  • [30] Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
    Windisch, Manfred
    Wolf, Hans-Joerg
    Hutter-Paier, Birgit
    Wronski, Robert
    CURRENT ALZHEIMER RESEARCH, 2007, 4 (05) : 556 - 561